News Press Releases

Synthetic Biologics to Present at the Biotech Showcase(TM) 2016 Conference

TOVX, PGEN | January 6, 2016

ROCKVILLE, Md., Jan. 6, 2016 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeff Riley, CEO, is scheduled to present at the Biotech Showcase^™ 2016 Conference next week in San Francisco, as follows:

Date: Monday, January 11, 2016
Time: 11:00 a.m. (PT) / 2:00 p.m. (ET)
Location: Parc 55 Wyndham San Francisco Union Square Hotel - Room: Market Street (3^rd Floor)

A live webcast of Synthetic Biologics' presentation may be accessed by logging onto the internet at http://edge.media-server.com/m/p/ax9f6zv8. After the presentation, a replay will be archived and accessible for 90 days at the same website.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company's lead candidates in Phase 2 development include: (1) SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS, and in collaboration with Intrexon Corporation (NYSE: XON), a preclinical stage monoclonal antibody for the prevention and treatment of Pertussis and discovery stage biotherapeutics for the treatment of phenylketonuria (PKU). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.